

| | | | |
|---|--|------------------------|-------------------|
| Substitute for form 1449A/PTO | | Complete If Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/485,583 |
| | | Filing Date | February 14, 2000 |
| | | First Named Inventor | Koichi ENDO |
| | | Group Art Unit | 1617 |
| | | Examiner Name | K. STILLER |
| | | Attorney Docket Number | ENDO=12 |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|----------------------|----------------------------|---|--|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number known) | Kind Code ² (if | | | |
| AB | AA | 5 6 2 9 3 2 2 | | Guthikonda, et al. | 05-13-1997 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|-----------------------|----------------------|---------------|-----------------------------------|---|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Office ³ | Number | Kind Code ⁵ (if known) | | | | |
| AB | AB | WO | 9 8 2 0 8 6 5 | A2 | Cold Spring Harbor Laboratory | 05-22-1998 | | |
| | AC | WO | 9 8 0 7 4 3 9 | A1 | Washington University | 02-26-1998 | | |
| | AD | WO | 9 6 1 8 6 1 6 | A1 | Merck & Co., Inc. | 06-20-1996 | | |
| | AE | WO | 9 6 1 4 8 4 2 | A1 | Merck & Co., Inc. | 05-23-1996 | | |
| AB | AF | WO | 9 5 3 4 5 3 4 | A1 | The Wellcome Foundation Limited | 12-21-1995 | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

| | | | |
|--------------------|------------------|-----------------|--------|
| Examiner Signature | <i>Alpina B.</i> | Date Considered | 5/8/02 |
|--------------------|------------------|-----------------|--------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|---|------|------------------------|-------------------|
| Substitute for form 1449A/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) FEB 28 2002 OFFICE OF THE UNITED STATES PATENT & TRADEMARK OFFICE | | Application Number | 09/485,583 |
| | | Filing Date | February 14, 2000 |
| | | First Named Inventor | Koichi ENDO |
| | | Group Art Unit | 1617 |
| | | Examiner Name | K. STILLER |
| | | Attorney Docket Number | ENDO=12 |
| Sheet 1 | of 2 | | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| AB | AG | OSDOBY, et al., "CA+ and Protein Kinase C Activation, but not Inflammatory Stimuli, Upregulate the Inducible Nitric Oxide Synthase of Osteoclasts Contributing to Inhibited Bone Resorption," Bone, 20(4 suppl.):13S (1997), | |
| | AH | EVANS, et al., "Nitric Oxide and Its Role in Orthopaedic Disease," Clinical Orthopaedics and Related Research. 312:275-294 (1995), | |
| | AI | KASTEN, et al., "Potentiation of Osteoclast Bone-resorption Activity by Inhibition of Nitric Oxide Synthase," Proc. Natl. Acad. Sci. USA. 91:3659-3573 (1994), | |
| AB | AJ | TSUKAHARA, et al., "Effect of Nitric Oxide Synthase Inhibitors on Bone Metabolism in Growing Rats," American Journal of Physiological Society. 270(5):E840-E845 (1996), | |
| | AK | HUKKANEN, et al., "Cytokine-Stimulated Expression of Inducible Nitric Oxide Synthase by Mouse, Rat, and Human Osteoblast-Like Cells and Its Functional Role in Osteoblast Metabolic Activity," Endocrinology. 136(12):5445-5453 (1996) | |
| AB | AL | LOWIK, et al., "Inducible Production of Nitric Oxide in Osteoblast-like Cells and in Fetal Mouse Bone Explants is Associated with Suppression of Osteoclastic Bone Resorption," J. Clin. Invest. 93:1465-1472 (1994) | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

RECEIVED

MAR 04 2002

TECH CENTER 1800/2900

| | | | |
|--------------------|--|-----------------|--------|
| Examiner Signature | | Date Considered | 6/8/02 |
|--------------------|--|-----------------|--------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of 1

Complete if Known

Application Number 09/485,583

Filing Date February 14, 2000

First Named Inventor Koichi ENDO et al.

Group Art Unit 1617

Examiner Name K. Stiller

Attorney Docket Number ENDO=12

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
|--------------------|-----------------------|---|----------------|
| AB | AA | S. H. RALSTON, "Nitric Oxide and Bone: What a Gas!", BRITISH JOURNAL OF RHEUMATOLOGY, Vol. 36, No. 8, pp. 831-838, August 1997. | |
| | AB | S. H. RALSTON and P.S. Grabowski, "Mechanisms of Cytokine Induced Bone Resorption: Role of Nitric Oxide, Cyclic Guanosine Monophosphate, and Prostaglandins", BONE, Vol. 19, No. 1, pp. 29-33, July 1996. | |
| | AC | Stuart H. RALSTON et al., "Nitric Oxide: A Cytokine-Induced Regulator of Bone Resorption", JOURNAL OF BONE AND MINERAL RESEARCH, Vol. 10, No. 7, pp. 1040-1049. 1995. | |
| | AD | Edward P. GARVEY et al., "Potent and Selective Inhibition of Human Nitric Oxide Synthases: Inhibition By Non-Aminno Acid Isothiureas", JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 269, No. 43, pp. 26669-26676, October 1994. | |
| | AE | Teresa SUNYER, et al., "Ca ²⁺ or Phorbol Ester But Not Inflammatory Stimuli Elevate Inducible Nitric Oxide Synthase Messenger Ribonucleic Acid and Nitric Oxide (NO) Release in Avian Osteoclasts: Autocrine NO Mediates Ca ²⁺ -Inhibited Bone Resorption", ENDOCRINOLOGY, Vol. 138, No. 5, pp. 2148-2162, May 1997.. | |
| | AF | M.L. BRANDI, et al., "Bidirectional Regulation of Osteoclast Function by Nitric Oxide Synthase Isoforms", PROC. NATL. ACAD. SCI., Vol. 92, pp. 2954-2958, March 1995. | |
| AB | AG | W. Ross TRACEY, et al., "In Vivo Pharmacological Evaluation of Two Novel Type II (Inducible) Nitric Oxide Synthase Inhibitors", CAN. J. PHYSIOL. PHARMACOL., Vol. 73, pp. 665-669, 1995. | |
| | AH | William MOORE, et al., "L-N ⁶ -(1-Iminoethyl)lysine: A Selective Inhibitor of Inducible Nitric Oxide Synthase", J. MED. CHEM., Vol. 37, No. 23, pp. 3886-3888, 1994. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner
SignaturDate
Considered

5/7/02

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.